MedTrace Logo

An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes

NCT00116207 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2016-07-29

Study results available
· View outcomes & findings →

Summary

The focus of this project is cardiovascular diabetic autonomic neuropathy (DAN). DAN affects the nerves that control heart rate and blood flow to the heart in people with diabetes. DAN may cause problems with the rhythm of the heartbeat or decrease blood flow to the heart. Three medications will be tested for their effectiveness in DAN.

Conditions

  • Diabetic Autonomic Neuropathy

Interventions

DRUG

ORAL ANTIOXIDANT

Comparison of triple antioxidant combination therapy vs placebo.

Sponsors & Collaborators

Principal Investigators

  • Eva L Feldman, MD, PhD · University of Michigan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Primary Completion
2009-09-30
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116207 on ClinicalTrials.gov